PFE - Pfizer Inc.
| Previous close | 40.16 |
| Open | 39.32 |
| Bid | 38.16 x 800 |
| Ask | 38.17 x 1800 |
| Day's range | 38.03 - 39.45 |
| 52-week range | 33.97 - 44.56 |
| Volume | 44,489,518 |
| Avg. volume | 19,881,598 |
| Market cap | 211.187B |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | 13.50 |
| EPS (TTM) | 2.83 |
| Earnings date | 27 Jan 2020 |
| Forward dividend & yield | 1.52 (3.78%) |
| Ex-dividend date | 29 Jan 2020 |
| 1y target est | 42.33 |
- Yahoo Finance
Apple, AMD earnings: What to know in markets Tuesday
Earnings season kicks into higher gear Tuesday with a slew of quarterly reports, but investors will be paying especially close attention to tech giant Apple and chipmaker Advanced Micro Devices.
- Yahoo Finance
Senators Elizabeth Warren and Bernie Sanders get a message from this private equity titan
Bain Capital co-chairman Steve Pagliuca tries to set the record straight on the private equity industry amid frequent attacks by two Democratic presidential hopefuls.
- Zacks
Allergan to Divest Brazikumab, Zenpep to Close AbbVie Merger
Allergan (AGN) to divest autoimmune candidate, brazikumab and drug Zenpep in connection with its pending merger with AbbVie.
- Zacks
Pfizer (PFE) Lags Q4 Earnings & Sales Estimates, Stock Down
Pfizer (PFE) misses estimates for fourth-quarter earnings and sales. Loss of patent protection for key drug Lyrica in 2019 hurts sales significantly.
- Business Wire
PFIZER REPORTS FOURTH-QUARTER AND FULL-YEAR 2019 RESULTS
Pfizer Inc. (NYSE: PFE) reported financial results for fourth-quarter and full-year 2019 and provided 2020 financial guidance.
- Zacks
Here's Why You Should Add BioDelivery Stock to Your Portfolio
Here are five reasons which make BioDelivery (BDSI)) a good investment option in 2020.
- Simply Wall St.
Pfizer Inc. (NYSE:PFE) Looks Interesting, And It's About To Pay A Dividend
Readers hoping to buy Pfizer Inc. (NYSE:PFE) for its dividend will need to make their move shortly, as the stock is...
- Financial Times
Why big pharma sees a remedy in data and AI
When Mac Holmes noticed a lump in the middle of his chest it took him a year to mention it to his physician. The 55-year-old, who flew packages for FedEx after a 28-year career with the US Air Force, appeared a picture of late middle-aged vigour. Days later he was diagnosed with breast cancer, a disease that has spread to his bones.
- Yahoo Finance
New partnership aims to ease surging generic drug costs— by making its own
A new partnership plans to bolster the U.S. supply of generic drugs, as part of a wide ranging effort to help drive down spiking costs and ease shortages.
- Zacks
What Lies Ahead for Healthcare ETFs in Q4 Earnings?
With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.
- Zacks
Pharma Stock Roundup: J&J's Mixed Q4, Roche & Novartis' New Drugs Approval in EU
J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.
- Zacks
Will Pfizer's (PFE) BioPharma Unit Boost Its Q4 Earnings?
Higher sales of Pfizer's (PFE) key brands, Eliquis, Xeljanz, Ibrance in the Biopharma segment are likely to have made up for lower sales in the Upjohn group.
- Business Wire
Pfizer Vaccines Launches Global Centers of Excellence Network to Conduct Real-World Research on Vaccine-Preventable Diseases Affecting Adults
Pfizer Inc. (NYSE: PFE) announced today the launch of its Vaccines Division’s Centers of Excellence Network, a global program of collaborations with academic institutions to conduct real-world epidemiologic research to accurately identify and measure the burden of specific vaccine-preventable diseases and potentially evaluate vaccine effectiveness affecting adults. Pfizer Vaccines has designated the University of Louisville as its first Center of Excellence with a second global center anticipated in the first half of 2020.
- Zacks
The Zacks Analyst Blog Highlights: Pfizer, Wells Fargo, SAP, salesforce.com and Eli Lilly
The Zacks Analyst Blog Highlights: Pfizer, Wells Fargo, SAP, salesforce.com and Eli Lilly
- Zacks
Pfizer (PFE) Q4 Earnings Coming Up: What's in the Cards?
While Pfizer's (PFE) key drugs like Ibrance, biosimilars and strong emerging market sales are likely to have driven Q4 sales, generic competition for Lyrica is likely to have hurt the same.
- Business Wire
Pfizer’s Greenstone and Digital Men’s Health Clinic Roman Collaborate to Offer Patients Remote Access to the Only FDA-Approved Authorized Generic Version of Viagra® (sildenafil citrate)
Greenstone, Upjohn’s U.S.-based generics business and a wholly owned subsidiary of Pfizer Inc., and Roman, an innovative digital healthcare clinic for men, today announced a supply agreement to offer Roman members access to the only FDA-approved authorized generic version of Viagra (sildenafil citrate). A division of the direct-to-patient telehealth company Ro, Roman provides patients access to a nationwide digital doctor’s office and online pharmacy for certain men’s health conditions through an integrated platform to enhance the convenience and quality of healthcare delivery. Greenstone has been a leader in authorized generics for more than 25 years and manufactures sildenafil citrate, a prescription medicine used to treat erectile dysfunction (ED). The exclusive supply agreement with Roman represents Greenstone’s first collaboration with a direct-to-patient telehealth company.
- Zacks
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
Pfizer (PFE) closed the most recent trading day at $40.19, moving -0.37% from the previous trading session.
- Zacks
Top Stock Analyst Reports for Pfizer, Wells Fargo & SAP
Top Stock Analyst Reports for Pfizer, Wells Fargo & SAP
- Zacks
Glaxo's Multiple Myeloma Candidate Gets FDA's Priority Review
Glaxo's (GSK) BLA for belantamab mafodotin gains the FDA priority review status to treat heavily pre-treated patients with relapsed or refractory multiple myeloma.
- Zacks
AstraZeneca Announces Positive FDA Updates on Cancer Drugs
AstraZeneca's (AZN) label expansion application for Lynparza in a prostate cancer indication gets priority review from the FDA. Imfinzi and pipeline candidate, tremelimumab get orphan drug status for liver cancer.
- Zacks
Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction
Novo Nordisk's (NVO) Ozempic gets FDA approval for reducing the risk of major adverse cardiovascular events in people with type II diabetes and established CVD.
- Zacks
Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA
The FDA accepts Bristol-Myers' (BMY) sBLA for the Opdivo-Yervoy combo for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.
- Bloomberg
Glaxo, Pfizer Executives Out of Step on Consumer Unit’s Future
(Bloomberg) -- U.K. drugmaker GlaxoSmithKline Plc hasn’t made plans to pursue an initial public offering of the consumer-health company it set up with Pfizer Inc. last year, a top executive said, distancing himself from remarks made by Pfizer’s chief executive a day earlier.The comments could expose a lack of communication between the two partners. Pfizer’s Chief Executive Officer Albert Bourla yesterday said he expected Glaxo to pursue an IPO in three to four years.“This is the time that we will be able to exit from this partnership, and I’m sure that this business will have a fantastic IPO,” Bourla said at the J.P. Morgan Healthcare Conference in San Francisco.An IPO isn’t the only option, said David Redfern, Glaxo’s chief strategy officer, in an interview at the meeting. Glaxo said at the time of the deal that it would separate and list the company within three to five years.“Actually we haven’t decided anything,” Redfern said Wednesday. “When we announced the deal, we said we expect it to separate within three years, but actually up to five years. And it’s entirely our decision.”Both Glaxo, the majority owner, and Pfizer, which has about a third of the business, are looking to focus on drug development. Recent shifts in the health-care business and in the broader economy have challenged a model in which drugmakers control every corner of home medicine cabinets.Redfern said the consumer business needed to focus on integration and growing sales, not a spinoff or IPO.“We don’t want it too distracted right now thinking about capital markets,” he said. “Whether it’s an IPO or just a straight spin, all options are on the table. We’ve literally had no discussion” with Pfizer on that topic.With annual sales of about $13 billion, the consumer venture has brought under one roof Advil painkillers, Tums stomach tablets, Sensodyne toothpaste and Nicorette gum.The world’s biggest supplier of over-the-counter medicines will be one of the industry’s only standalones, facing off with companies integrated into larger entities such as Johnson & Johnson, Bayer AG and Procter & Gamble Co.\--With assistance from Mark Schoifet.To contact the reporter on this story: Riley Griffin in New York at rgriffin42@bloomberg.netTo contact the editor responsible for this story: Drew Armstrong at darmstrong17@bloomberg.netFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
- Yahoo Finance
Influencers Transcript: Robert F. Kennedy, Jr., January 16, 2020
Yahoo Finance Editor-in-Chief Andy Serwer sits down with Chairman of the Children’s Health Defense, and President of the Waterkeeper Alliance, Robert F. Kennedy, Jr.
- Financial Times
Hedge fund veteran looks to cash in on biotech boom
Dixon Boardman, a veteran of the hedge fund industry, is launching a biotech-themed fund, trying to cash on in a wave of investor interest in one of the best performing segments of the US stock market. The New York-based fund manager, who set up Optima Fund Management in 1988 when the industry was in its infancy, plans to launch the fund to invest in a basket of five biotechnology-focused hedge funds, some of which are closed to new investors. The launch comes after the S&P biotech sector doubled since February 2016.
